These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, Bosch J. Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642 [Abstract] [Full Text] [Related]
13. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Aliment Pharmacol Ther; 2002 Mar; 16(3):373-80. PubMed ID: 11876689 [Abstract] [Full Text] [Related]
15. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol. Aramaki T, Sekiyama T, Katsuta Y, Kurokawa H, Komeichi H, Tsutsui H, Terada H, Ohsuga M, Satomura K, Okumura H. J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676 [Abstract] [Full Text] [Related]
17. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755 [Abstract] [Full Text] [Related]